This inventor holds 65 USPTO granted patents and 4 published patent applications, plus 8 CIPO patents and 33 EPO patents, primarily in Histone Deacetylase Inhibitors (CPC class C07D). Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited, Other. Active years: 2005-2022.
Inventors with similar research interests:
Location History:
- Issy-les-Moulineaux Cedex FR (2006)
- Fontaine-Bellinger, FR (2013)
- Val de Reuil, FR (2016)
- Fontaine-Bellenger, FR (2005 - 2019)
- Saint Pierre d'Autils, FR (2020)
- Issy-les Moulineaux, FR (2021 - 2022)
Company Filing History:
49 out of 2,099 
14 out of 126 
2 out of 834,411 Years Active: 2005-2022
Areas of Expertise:
Title: **Patrick René Angibaud: A Pioneer in Pharmaceutical Innovations**
Introduction
Patrick René Angibaud, based in Fontaine-Bellenger, France, is a distinguished inventor known for his significant contributions in the field of pharmaceuticals. With an impressive portfolio of 65 patents, Angibaud has made remarkable advancements that address critical health issues, particularly in cancer, myelodysplastic syndrome (MDS), and diabetes.
Latest Patents
Among his latest innovations are two notable patents. The first, titled "Exo-aza spiro inhibitors of menin-MLL interaction," introduces compounds capable of inhibiting the menin/MLL protein/protein interaction. These compounds hold potential in treating various diseases, including cancer and diabetes. The second patent focuses on "Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors." This invention outlines substituted quinoxaline and pyridopyrazine derivatives that function as PI3K-beta inhibitors, offering new possibilities for pharmaceutical compositions and clinical applications.
Career Highlights
Throughout his career, Angibaud has worked with prominent companies, notably Janssen Pharmaceutica and Astex Therapeutics Limited. His work with these organizations has not only expanded his expertise but also contributed to developing groundbreaking medical solutions.
Collaborations
Collaboration has played a vital role in Angibaud's success. He has worked alongside esteemed coworkers, including Isabelle Noëlle Constance Pilatte and Bruno Roux, which has fostered an environment of innovation and creativity, leading to the development of numerous patents that drive advancements in healthcare.
Conclusion
Patrick René Angibaud stands out as a key figure in pharmaceutical innovation. His dedication to research and development has enabled significant strides in treating complex diseases. With a strong foundation of patents and collaborations, Angibaud continues to be a driving force in the quest to enhance patient outcomes and revolutionize medical treatments.